Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Cynthia Campbell-Baird"'
Autor:
Ahmed A Alkhateeb, Kim Leitzel, Suhail M Ali, Cynthia Campbell-Baird, Matthew Evans, Eva-Maria Fuchs, Wolfgang J Köstler, Allan Lipton, James Connor
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e51379 (2012)
Approximately half of all HER2/neu-overexpressing breast cancer patients do not respond to trastuzumab-containing therapy. Therefore, there remains an urgent and unmet clinical need for the development of predictive biomarkers for trastuzumab respons
Externí odkaz:
https://doaj.org/article/24029cb6545c4b4c9ef138c830617ed0
Autor:
F Gatta, Stacey Harrelson, Yi Qian, Ateesha F. Mohamed, Juan Marcos Gonzalez, Jorge Arellano, Cynthia Campbell-Baird, A. Brett Hauber, Guy Hechmati
Publikováno v:
The Patient
Background Bone-targeted agents (BTAs) used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease possess different attributes that factor into treatment decisions. Objective The aim of this study was to evaluat
Autor:
Xavier M. Anguela, Katie Wachtel, Judith Kadosh, Stacy E. Croteau, Marcus E. Carr, Lindsey A. George, Leonard A. Valentino, Matthew S. Evans, Federico Mingozzi, Linda B. Couto, Daniel Takefman, Kathleen B Reape, Daniel J. Hui, Alexa R. Runoski, Amy Macdougall, Katherine A. High, Cynthia Campbell-Baird, Marcelyne Joseney-Antoine, Ben J. Samelson-Jones, Howard Hait, Summer Tompkins, Spencer K. Sullivan, Ashlyn Eaton Bassiri, M. Elaine Eyster, Kayla Douglas, Margaret V. Ragni
Publikováno v:
Blood. 132:487-487
Gene transfer for hemophilia A offers the potential for a one-time disease altering treatment, eliminating the risk of bleeds while freeing patients from the burden of lifelong chronic therapy. SPK-8011 consists of a bioengineered AAV capsid expressi
Autor:
John A. Glaspy, Virginia Seery, Mark M. Schubert, Joyce O'Shaughnessy, Timothy F. Meiller, Hope S. Rugo, Brian L. Schmidt, Cynthia Campbell-Baird, Chi T. Viet, Jan W. Hronek, Josephine Divers, Douglas E. Peterson, Sharon Elad
Publikováno v:
Cancer Medicine
Cancer medicine, vol 5, iss 8
Cancer medicine, vol 5, iss 8
In recent years oral mucosal injury has been increasingly recognized as an important toxicity associated with mammalian target of rapamycin (mTOR) inhibitors, including in patients with breast cancer who are receiving everolimus. This review addresse
Autor:
Suhail M. Ali, Allan Lipton, James D. Connor, Cynthia Campbell-Baird, Kim Leitzel, W. Koestler, Ahmed Alkhateeb, E-M Fuchs, Matt Evans
Publikováno v:
Cancer Research. 71:P5-14
Background: Approximately one-half of HER2−positive breast cancer patients will not respond to first-line trastuzumab-containing therapy. Since trastuzumab is now used in the HER2−positive adjuvant breast cancer setting, trastuzumab resistance wi
Autor:
Junjia Zhu, Shaman Luo, Elizabeth Packard, Gang Chen, Cristina I. Truica, Leah Cream, Cynthia Campbell-Baird, Kim Leitzel, Philip Lazarus
Publikováno v:
Journal of Clinical Oncology. 36:e12534-e12534
e12534Background: Genetic polymorphisms in drug metabolizing enzymes can have significant impact on drug toxicity and/or efficacy. Exemestane (Exe), a steroidal aromatase inhibitor, is extensively ...
Publikováno v:
Community Oncology. 7:85-89
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 23(12)
Antiresorptive therapies are used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease related to breast cancer, prostate cancer, and other solid tumors. This review highlights the central role of nurses in sup
Autor:
Lindsey Zubritsky, Cynthia Campbell-Baird, Brian J. Kinsman, Ahmed Alkhateeb, Allan Lipton, Suhail M. Ali, James R. Connor, Kim Leitzel
Publikováno v:
Journal of gastrointestinal cancer. 45(2)
Cancer-associated inflammation plays a driver role in pancreatic tumor development and progression. Moreover, recent studies have implicated the inflammatory tumor microenvironment in modulating therapy response and inducing resistance. The aim of th
Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer
Publikováno v:
Journal of Clinical Gastroenterology. 44:286-288
Goals and background Cyclooxygenase-2 (COX-2) has been shown to be expressed in a variety of tumors including pancreatic cancer. The combination of gemcitabine and irinotecan is active in pancreatic cancer. The purpose of this study is to determine t